Cargando…

Correction: DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472168/ https://www.ncbi.nlm.nih.gov/pubmed/36096537 http://dx.doi.org/10.1136/jitc-2021-004322corr1

Ejemplares similares

DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
por: Muik, Alexander, et al.
Publicado: (2022)

Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models
por: Kemper, Kristel, et al.
Publicado: (2022)

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
por: Wenthe, Jessica, et al.
Publicado: (2020)

Multimeric forms of CD40 ligand (CD40L), 4-1BB ligand (4-1BBL), OX40 ligand (OX40L), CD27L/CD70, and other TNFSFs as tools for adoptive cell therapy
por: Kornbluth, Richard S
Publicado: (2013)

A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors
por: Konstorum, Anna, et al.
Publicado: (2019)

4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)

OX40 and 4-1BB delineate distinct immune profiles in sarcoma
por: Melake, MJ, et al.
Publicado: (2022)

4‐1BB costimulation promotes bystander activation of human CD8 T cells
por: Reithofer, Manuel, et al.
Publicado: (2020)

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
por: Wenthe, Jessica, et al.
Publicado: (2021)

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
por: Engelberts, Patrick J., et al.
Publicado: (2020)

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism
por: Medler, Juliane, et al.
Publicado: (2022)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal
Publicado: (1993)

Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors
por: Mascarelli, Daniele E., et al.
Publicado: (2021)

Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies
por: Mikkelsen, Kasper, et al.
Publicado: (2019)

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
por: Wenthe, Jessica, et al.
Publicado: (2023)

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
por: Hamid, Omid, et al.
Publicado: (2022)

CD8(+) T Cells Mediate CD40-independent Maturation of Dendritic Cells In Vivo
por: Ruedl, Christiane, et al.
Publicado: (1999)

The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells
Publicado: (1991)

Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
por: Zhao, Yuan, et al.
Publicado: (2012)

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
por: Zapata, Juan M., et al.
Publicado: (2018)

Biphasic role of 4-1BB in the regulation of mouse cytomegalovirus-specific CD8(+) T cells
por: Humphreys, Ian R, et al.
Publicado: (2010)

4-1BB Signaling Breaks the Tolerance of Maternal CD8(+) T Cells That Are Reactive with Alloantigens
por: Kim, Kwang H., et al.
Publicado: (2012)

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
por: Bartkowiak, Todd, et al.
Publicado: (2015)

Higher CD4(+)CD40(+) T cells (Th40 cells) associate with systemic lupus erythematosus activity
por: Zhu, Lihua, et al.
Publicado: (2023)

4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8(+) T Cells in Hepatocellular Carcinoma
por: Kim, Hyung‐Don, et al.
Publicado: (2019)

4-1BB-4-1BBL cis-interaction contributes to the survival of self-reactive CD8(+) T cell
por: Cho, Eunjung, et al.
Publicado: (2023)

Extracellular vesicles produced by immunomodulatory cells harboring OX40 ligand and 4-1BB ligand enhance antitumor immunity
por: Semionatto, Isadora Ferraz, et al.
Publicado: (2020)

CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
por: Saoulli, Katina, et al.
Publicado: (1998)

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2019)

PD-1 abrogates the prolonged persistence of CD8(+) CAR-T cells with 4-1BB co-stimulation
por: Li, Feng, et al.
Publicado: (2020)

Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
por: Song, Chang, et al.
Publicado: (2014)

4‐1BB and cytokines trigger human NK, γδ T, and CD8(+) T cell proliferation and activation, but are not required for their effector functions
por: Vidard, Laurent
Publicado: (2022)

TCR-independent CD137 (4–1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation
por: Pichler, Andrea C., et al.
Publicado: (2023)

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2020)

The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation
por: Sum, Eva, et al.
Publicado: (2022)

Exposure of a Distinct PDCA-1(+) (CD317) B Cell Population to Agonistic Anti-4-1BB (CD137) Inhibits T and B Cell Responses Both In Vitro and In Vivo
por: Vinay, Dass S., et al.
Publicado: (2012)

Activation of human dendritic cells through CD40 cross-linking
Publicado: (1994)

4-1BB (CD137) and radiation therapy: A case report and literature review
por: Shiao, Jay C., et al.
Publicado: (2017)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f5h579mgif08nlslmv6coc5om5